Annual CFO
-$18.07 M
-$2.31 M-14.67%
01 December 2023
Summary:
TransCode Therapeutics annual cash flow from operations is currently -$18.07 million, with the most recent change of -$2.31 million (-14.67%) on 01 December 2023. During the last 3 years, it has fallen by -$12.81 million (-243.17%). RNAZ annual CFO is now -3566.23% below its all-time high of -$493.00 thousand, reached on 31 December 2020.RNAZ Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.91 M
-$1.57 M-67.22%
01 September 2024
Summary:
TransCode Therapeutics quarterly cash flow from operations is currently -$3.91 million, with the most recent change of -$1.57 million (-67.22%) on 01 September 2024. Over the past year, it has increased by +$1.75 million (+30.92%). RNAZ quarterly CFO is now -21516.57% below its all-time high of -$18.10 thousand, reached on 01 March 2020.RNAZ Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$15.85 M
-$406.80 K-2.63%
01 September 2024
Summary:
TransCode Therapeutics TTM cash flow from operations is currently -$15.85 million, with the most recent change of -$406.80 thousand (-2.63%) on 01 September 2024. Over the past year, it has increased by +$2.22 million (+12.29%). RNAZ TTM CFO is now -87486.19% below its all-time high of -$18.10 thousand, reached on 01 March 2020.RNAZ TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +30.9% | +12.3% |
| 3 y3 years | -243.2% | -144.4% | -201.0% |
| 5 y5 years | -3454.5% | - | - |
RNAZ Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -243.2% | at low | -144.4% | +30.9% | -201.0% | +12.3% |
| 5 y | 5 years | -3566.2% | at low | <-9999.0% | +30.9% | <-9999.0% | +12.3% |
| alltime | all time | -3566.2% | at low | <-9999.0% | +30.9% | <-9999.0% | +12.3% |
TransCode Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.91 M(+67.2%) | -$15.85 M(+2.6%) |
| June 2024 | - | -$2.34 M(-40.6%) | -$15.45 M(-11.7%) |
| Mar 2024 | - | -$3.94 M(-30.5%) | -$17.50 M(-3.2%) |
| Dec 2023 | -$18.07 M(+14.7%) | -$5.66 M(+61.5%) | -$18.07 M(+10.0%) |
| Sept 2023 | - | -$3.51 M(-20.2%) | -$16.43 M(-5.3%) |
| June 2023 | - | -$4.39 M(-2.7%) | -$17.35 M(+6.2%) |
| Mar 2023 | - | -$4.51 M(+12.3%) | -$16.33 M(+3.6%) |
| Dec 2022 | -$15.76 M | -$4.02 M(-9.1%) | -$15.76 M(+18.1%) |
| Sept 2022 | - | -$4.42 M(+31.1%) | -$13.34 M(+11.3%) |
| June 2022 | - | -$3.37 M(-14.6%) | -$11.99 M(+37.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.95 M(+146.7%) | -$8.69 M(+65.1%) |
| Dec 2021 | -$5.27 M(+968.3%) | -$1.60 M(-47.8%) | -$5.27 M(+34.3%) |
| Sept 2021 | - | -$3.07 M(+3936.8%) | -$3.92 M(+298.3%) |
| June 2021 | - | -$76.00 K(-85.4%) | -$984.50 K(-1.3%) |
| Mar 2021 | - | -$522.20 K(+104.4%) | -$997.00 K(+102.3%) |
| Dec 2020 | -$493.00 K(-3.0%) | - | - |
| Dec 2020 | - | -$255.50 K(+95.3%) | -$492.90 K(+107.6%) |
| Sept 2020 | - | -$130.80 K(+47.8%) | -$237.40 K(+122.7%) |
| June 2020 | - | -$88.50 K(+389.0%) | -$106.60 K(+489.0%) |
| Mar 2020 | - | -$18.10 K | -$18.10 K |
| Dec 2019 | -$508.50 K | - | - |
FAQ
- What is TransCode Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly CFO year-on-year change?
- What is TransCode Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for TransCode Therapeutics?
- What is TransCode Therapeutics TTM CFO year-on-year change?
What is TransCode Therapeutics annual cash flow from operations?
The current annual CFO of RNAZ is -$18.07 M
What is the all time high annual CFO for TransCode Therapeutics?
TransCode Therapeutics all-time high annual cash flow from operations is -$493.00 K
What is TransCode Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RNAZ is -$3.91 M
What is the all time high quarterly CFO for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly cash flow from operations is -$18.10 K
What is TransCode Therapeutics quarterly CFO year-on-year change?
Over the past year, RNAZ quarterly cash flow from operations has changed by +$1.75 M (+30.92%)
What is TransCode Therapeutics TTM cash flow from operations?
The current TTM CFO of RNAZ is -$15.85 M
What is the all time high TTM CFO for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM cash flow from operations is -$18.10 K
What is TransCode Therapeutics TTM CFO year-on-year change?
Over the past year, RNAZ TTM cash flow from operations has changed by +$2.22 M (+12.29%)